- Home
- XELB vs NERV Comparison
XELB vs NERV Comparison
Compare XELB & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XELB
- NERV
- Stock Information
- Founded
- XELB 2011
- NERV 2007
- Country
- XELB United States
- NERV United States
- Employees
- XELB N/A
- NERV N/A
- Industry
- XELB Multi-Sector Companies
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- XELB Miscellaneous
- NERV Health Care
- Exchange
- XELB Nasdaq
- NERV Nasdaq
- Market Cap
- XELB 19.0M
- NERV 16.0M
- IPO Year
- XELB N/A
- NERV 2014
- Fundamental
- Price
- XELB $0.43
- NERV $2.23
- Analyst Decision
- XELB
- NERV Hold
- Analyst Count
- XELB 0
- NERV 1
- Target Price
- XELB N/A
- NERV $5.00
- AVG Volume (30 Days)
- XELB 376.5K
- NERV 37.0K
- Earning Date
- XELB 12-20-2024
- NERV 02-20-2025
- Dividend Yield
- XELB N/A
- NERV N/A
- EPS Growth
- XELB N/A
- NERV N/A
- EPS
- XELB N/A
- NERV N/A
- Revenue
- XELB $9,337,000.00
- NERV N/A
- Revenue This Year
- XELB N/A
- NERV N/A
- Revenue Next Year
- XELB $74.82
- NERV N/A
- P/E Ratio
- XELB N/A
- NERV N/A
- Revenue Growth
- XELB N/A
- NERV N/A
- 52 Week Low
- XELB $0.33
- NERV $2.06
- 52 Week High
- XELB $1.70
- NERV $13.49
- Technical
- Relative Strength Index (RSI)
- XELB 37.11
- NERV 50.40
- Support Level
- XELB $0.42
- NERV $2.07
- Resistance Level
- XELB $0.48
- NERV $2.39
- Average True Range (ATR)
- XELB 0.05
- NERV 0.12
- MACD
- XELB 0.00
- NERV -0.01
- Stochastic Oscillator
- XELB 17.45
- NERV 48.48
About XELB Xcel Brands Inc.
Xcel Brands Inc is a media and brand management company. It is engaged in design, merchandising and planning, sourcing and production, licensing, marketing, and brand development. The company offers branded apparel, footwear, accessories, jewelry, home goods, and other consumer products. Its brand portfolio consists of the Isaac Mizrahi, Judith Ripka, H Halston, C Wonder, and the Highline Collective brands. The company licenses its brands to third parties, provides certain design, production, and marketing services, and generates licensing, design, and service fee revenues through contractual arrangements and other agreements.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.